An Accelerated Red-Cell Hemagglutination Inhibition Immunoassay for Measuring Fibrinogen Degradation Products in Human Serum

R Fischer; M Furlan; E. A Beck

doi:10.1055/s-0038-1653678

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1971; 26(02): 311-314
DOI: 10.1055/s-0038-1653678

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

An Accelerated Red-Cell Hemagglutination Inhibition Immunoassay for Measuring Fibrinogen Degradation Products in Human Serum

R Fischer

¹Central Hematology Laboratory, Inselspital, and University of Berne, School of Medicine, Berne, Switzerland

,

M Furlan

¹Central Hematology Laboratory, Inselspital, and University of Berne, School of Medicine, Berne, Switzerland

,

E. A Beck^*

¹Central Hematology Laboratory, Inselspital, and University of Berne, School of Medicine, Berne, Switzerland

› Author Affiliations

Abstract

Summary

A further modification of Merskey’s hemagglutination inhibition assay for measurement of fibrinogen degradation products (FDP) in human serum was developed. Blood is clotted in the presence of protamine chloride (25 u/ml), in addition to thrombin and s-aminocaproic acid, and at room temperature. Defibrination is complete within 5 min even in blood obtained from patients on heparin treatment. The hemagglutination immunoassay was also considerably accelerated by immediate addition of sensitized red cells to the mixtures of antiserum and antigen dilutions at 37° C. Accurate readings of FDP titers may thus be obtained within 20 min following venipuncture.

Full Text

References

References
1 Derechin M. Caractères généraux de la paracoagulation fibrinoly tique. Rev. Hémat 10: 35 1955;
2 Marder V. J, Shulman N. R. High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. J. Biol. Chem 244: 2120 1969;
3 Marder V. J, Shulman N. R, Carroll W. R. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunochemical characterization. J. Biol. Chem 244: 2111 1969;
4 Merskey C, Kleiner G. J, Johnson A. J. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1 1966;
5 Merskey G, Lalezari P, Johnson A. J. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc. Soc. exp. Biol. (N. Y) 131: 871 1969;
6 Thomas D. P, Niewiarowski S, Myers A. R, Bloch K. J, Colman R. W. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. New Engl. J. Med 283: 663 1970;
7 Triantaphyllopoulos D. C. Anticoagulant effect of incubated fibrinogen. Canad. J. Biochem 36: 250 1958;